GPC3 and hepatocellular carcinoma: Despite these advances in molecular diagnosis of HCC, Nam SW and his colleagues proposed a 3-gene signature, including GPC3, LYVE1 and survivin as an accurate molecular tool (>80 % accuracy) to discriminate dysplastic nodules and small HCC <2 cm in size, but restricted to HCV-related HCC [18].